牛牛AI助理已提取核心訊息
SeaStar Medical, a medical technology company, has filed an amended annual report for the fiscal year ended December 31, 2023. The amendment, submitted on July 3, 2024, includes additional exhibits that were inadvertently omitted from the original filing with the Securities and Exchange Commission (SEC) on April 16, 2024, and the subsequent amendment on April 26, 2024. The exhibits added pertain to various agreements and warrants related to the company's financial and business dealings. No other changes have been made to the original report, and the amendment does not reflect any new information post the original filing date. The company's aggregate market value of common equity held by non-affiliates was reported at $23,606,503 as of July 3, 2024, with 3,221,104 shares of common stock outstanding as of July 5, 2024. SeaStar...Show More
SeaStar Medical, a medical technology company, has filed an amended annual report for the fiscal year ended December 31, 2023. The amendment, submitted on July 3, 2024, includes additional exhibits that were inadvertently omitted from the original filing with the Securities and Exchange Commission (SEC) on April 16, 2024, and the subsequent amendment on April 26, 2024. The exhibits added pertain to various agreements and warrants related to the company's financial and business dealings. No other changes have been made to the original report, and the amendment does not reflect any new information post the original filing date. The company's aggregate market value of common equity held by non-affiliates was reported at $23,606,503 as of July 3, 2024, with 3,221,104 shares of common stock outstanding as of July 5, 2024. SeaStar Medical's business development activities over the past year included a series of agreements and partnerships, such as a merger plan with LMF Acquisition Opportunities, Inc., and a license and distribution agreement with NuWellis, Inc. The company's future plans and strategic initiatives were not detailed in the amendment. SeaStar Medical is categorized as a non-accelerated filer, smaller reporting company, and emerging growth company, indicating its current stage of development.
醫療科技公司SeaStar Medical已提交修訂後的2023年財政年度年度報告。該修訂版於2024年7月3日提交，包含了原始文件中在2024年4月16日提交給證券交易委員會（SEC）的文件中無意遺漏的附加展示，以及2024年4月26日的後續修訂。新增的展示涉及公司財務和業務往來的各種協議和權證。原報告未作任何其他更改，修訂版未反映任何原提交日期後的新信息。截至2024年7月3日，該公司非關聯股東持有的普通股總市值爲23,606,503美元，截至2024年7月5日，其普通股流通股爲3,221,104股。過去一年，SeaStar Medical的業務發展活動包括一系列協議和合作夥伴關係，如與L...展開全部
醫療科技公司SeaStar Medical已提交修訂後的2023年財政年度年度報告。該修訂版於2024年7月3日提交，包含了原始文件中在2024年4月16日提交給證券交易委員會（SEC）的文件中無意遺漏的附加展示，以及2024年4月26日的後續修訂。新增的展示涉及公司財務和業務往來的各種協議和權證。原報告未作任何其他更改，修訂版未反映任何原提交日期後的新信息。截至2024年7月3日，該公司非關聯股東持有的普通股總市值爲23,606,503美元，截至2024年7月5日，其普通股流通股爲3,221,104股。過去一年，SeaStar Medical的業務發展活動包括一系列協議和合作夥伴關係，如與LMF Acquisition Opportunities, Inc.進行的合併計劃以及與NuWellis, Inc.簽訂的許可和分銷協議。修訂版中未詳細說明該公司的未來計劃和戰略舉措。SeaStar Medical被歸類爲非加速報告人、較小的報告公司和新興增長公司，表明其目前的發展階段。
有用
沒用
譯文內容由第三人軟體翻譯。
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了